For patients ≥1 year of age with SHORT BOWEL SYNDROME (SBS) who are dependent on parenteral support (PS)*
LESS PARENTERAL SUPPORT.
MORE TIME DOING WHAT THEY LOVE.
*In a 6-month clinical study (N=86), 63% of adult patients treated with GATTEX reduced their weekly PS volume by ≥20% (vs 30% with placebo) and 54% achieved a reduction of ≥1 day off PS per week (vs 23% with placebo).1
GATTEX PATIENT
GATTEX is the first and only FDA-approved glucagon-like peptide-2 (GLP-2) analog for patients ≥1 year of age with short bowel syndrome (SBS) who are dependent on parenteral support (PS)1
In clinical studies of patients with short bowel syndrome (SBS), GATTEX was proven to1:
Significantly reduce weekly parenteral support (PS) VOLUME requirements
Help patients achieve more TIME off of parenteral support (PS)
Help some patients achieve complete FREEDOM from parenteral support (PS)
In a 6-month study, adult patients treated with GATTEX reduced weekly PS volume by ≥20% (27/43) vs placebo (13/43) and achieved a reduction of ≥1 day off PS per week (21/39) vs placebo (9/39). In a 24-month open-label extension, adult patients previously treated with GATTEX weaned off PS completely after 30 months of treatment (10/30). In a 6-month study, pediatric patients treated with GATTEX reduced weekly PS volume by ≥20% (18/26), achieved a reduction of ≥1 day off PS per week (10/26), and weaned off PS completely (3/26).
Gattex Results In Adults Gattex Results In Pediatrics ≥1 YEAR
About Short Bowel Syndrome (SBS)
Learn about SBS and how your patients could be affected.
Learn About SBSGetting Started With GATTEX
Steps to getting your appropriate patients started on GATTEX (teduglutide) .
Get StartedAccess Resources
Download forms, brochures, and much more for use by you, your office staff, and your patients.
Find RESOURCESRequest A RepRESENTATIVE
Get support from a GATTEX (teduglutide) representative. Help may be virtual, over the phone, or in person, depending on circumstances.
Contact UsBETSY,
GATTEX PATIENT
ROY,
GATTEX PATIENT